2023 World Conference on Lung Cancer (Posters)-EP11.01. Study on Biomarkers for Predictive the Clinical Efficacy of Non-small Cell Lung Cancer Immunotherapy

EP11.01. Study on Biomarkers for Predictive the Clinical Efficacy of Non-small Cell Lung Cancer Immunotherapy - PDF(Abstract)

Back to course

Pdf Summary

This study explores the use of biomarkers to predict the clinical efficacy of immunotherapy in non-small cell lung cancer (NSCLC) patients. The efficacy of immune checkpoint blockade (ICB) varies among NSCLC patients, and regulatory T cells (Tregs) play a role in tumor immune escape. The objective of this paper is to investigate the clinical value of T lymphocyte subset count and Tregs in predicting the efficacy of immunotherapy in NSCLC patients.<br /><br />Peripheral blood samples were collected from 48 NSCLC patients and 48 healthy volunteers. The T lymphocyte subset count and the percentage of Tregs cells were measured using flow cytometry, and clinical data and other biochemical indicators were collected for both groups.<br /><br />The results show that NSCLC patients had lower T lymphocyte subset counts and higher levels of Tregs cells compared to healthy volunteers. In the patient group, there were differences in T lymphocyte subsets based on clinicopathological factors such as clinical stage and presence of bone metastasis. Tregs cells were significantly increased in the non-smoking group. Multivariate analysis revealed that Tregs cell ratio, clinical stage, and PS score were independent influencing factors on progression-free survival (PFS) after adjusting for confounding factors.<br /><br />In conclusion, high levels of CD3 count, CD4 count, CD4/CD8 ratio, and low levels of peripheral Tregs can serve as predictive biomarkers for better prognosis in NSCLC patients. Peripheral blood Tregs may also be an independent predictor of NSCLC progression and could be used for personalized treatment options.<br /><br />Keywords: Tregs, Biomarker, NSCLC<br /><br />Overall, this research suggests that certain biomarkers can be used to predict the effectiveness of immunotherapy in NSCLC patients and guide personalized treatment strategies.

Asset Subtitle

Tong Cui

Meta Tag

Speaker Tong Cui

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

biomarkers

immunotherapy

non-small cell lung cancer

NSCLC

clinical efficacy

immune checkpoint blockade

T lymphocyte subset count

Tregs

predictive biomarkers

personalized treatment